Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.37 |
| ▸ | LCK | P06239 | 3/20 | 0.37 |
| ▸ | CSF1R | P07333 | 3/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.37 |
| ▸ | FLT1 | P17948 | 3/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.37 |
| ▸ | TAOK1 | Q7L7X3 | 3/20 | 0.37 |
| ▸ | RET | P07949 | 2/20 | 0.37 |
| ▸ | CLK2 | P49760 | 2/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380530 | 0.89 | KDR (0.43) | KDRAURKBAURKAMAPTMAP4K4 | |
| SCHEMBL379479 | 0.84 | PKM (0.43) | KDRMAPTHSD17B10FGFR1CLK4 | |
| SCHEMBL379851 | 0.82 | MAPT (0.38) | KDRAURKBAURKAMAPTHSD17B10 | |
| SCHEMBL380700 | 0.81 | KDR (0.44) | KDRAURKBAURKAMAP4K4LCK | |
| SCHEMBL2368856 | 0.80 | FGFR1 (0.56) | KDRAURKBAURKAMAP4K4LCK | |
| SCHEMBL379789 | 0.71 | KDR (0.44) | KDRAURKBAURKAMAPTHSD17B10 | |
| SCHEMBL380011 | 0.67 | UTS2R (0.53) | MAPTHSD17B10CLK4DYRK1ADYRK1B | |
| SCHEMBL5466369 | 0.65 | LMNA (0.50) | KDRAURKBAURKAMAP4K4LCK | |
| SCHEMBL28803622 | 0.65 | KDR (0.79) | KDRAURKBAURKAMAPTMAP4K4 | |
| SCHEMBL379746 | 0.64 | KDR (0.39) | KDRAURKBAURKAMAP4K4LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968982-B1 | THIENO (3,2-C) PYRIDINE COMPOUNDS | XENTION LTD (GB) | 2012-01-25 | — | — | EP | claimed |
| EP-1968982-A2 | THIENO (3,2-C) PYRIDINE COMPOUNDS | Xention Discovery Ltd. (GB) | 2008-09-17 | — | — | EP | claimed |
| US-20070161672-A1 | Compounds | XENTION LIMITED | 2007-07-12 | — | — | US | claimed |
| WO-2007066127-A2 | THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS | XENTION LIMITED (GB) | 2007-06-14 | — | — | WO | claimed |
| US-9216992-B2 | Thieno[3,2-c]pyridine potassium channel inhibitors | XENTION LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
| EP-1968982-B1 | THIENO (3,2-C) PYRIDINE COMPOUNDS | XENTION LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1968982-A2 | THIENO (3,2-C) PYRIDINE COMPOUNDS | Xention Discovery Ltd. (GB) | 2008-09-17 | — | — | EP | disclosed |
| US-20070161672-A1 | Compounds | XENTION LIMITED | 2007-07-12 | — | — | US | disclosed |
| WO-2007066127-A2 | THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS | XENTION LIMITED (GB) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161672-A1 | Compounds | KCNJ2, KCNT1, KCNT2 | KDR 2522/4885AURKB 2258/4885AURKA 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.